November 20, 2024

$70.2 million of Net Revenue Q3 2024 +34.6% Comparable Net Revenue Growth Both brands accelerating from Q2 2024 +45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023 Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023 LONDON, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD)

October 7, 2024
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that Hind Sebti, Kelly Brookie and Roberto Thompson have been appointed to its board of Directors (the “Board”), effective
August 27, 2024
$63.3 million of Net Revenue Q2 2024 +25.7% net revenue Comparable Growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023 NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global
May 30, 2024
WHITE PLAINS, N.Y., May 30, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the Company will participate in upcoming investor conferences. On June 5, 2024, the Company will participate in
May 21, 2024
$68.3 million of Net Revenue +21.0% Comparable Net Revenue: +20.6% Obagi Skincare and +21.5% Milk Makeup Adjusted EBITDA of $11.4 million, up +12.9% vs Q1 2023 WHITE PLAINS, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand
Displaying 1 - 10 of 22
Print Page
Investor FAQs
RSS Feeds
Email Alerts
Contact IR